Clinical Consultations™ in Neurotrophic Keratitis (CME Symposium)
Target Audience
This educational activity is intended for ophthalmologists.
Learning Objectives
After completing this activity, participants will be better able to:
- Describe the role of corneal sensory innervation in ocular surface health
- Integrate evaluation of corneal sensitivity into assessment of ocular surface disease
- Interpret evidence of corneal healing and reinnervation in patients treated with recombinant
human nerve growth factor - Select treatment strategies for patients diagnosed with any stage of neurotrophic keratitis
Faculty
Stephen C. Pflugfelder, MD (Chair)
Professor of Ophthalmology
James and Margaret Elkins Chair
Baylor College of Medicine
Houston, Texas
Kendall E. Donaldson, MD, MS
Professor of Clinical Ophthalmology
Medical Director
Bascom Palmer Eye Institute in Plantation
Plantation, Florida
Christopher J. Rapuano, MD
Professor of Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Chief, Cornea Service
Wills Eye Hospital
Philadelphia, Pennsylvania
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Kendall E. Donaldson, MD, MS, is a consultant for Alcon, Allergan, Avellino, Bausch & Lomb Incorporated, Carl Zeiss Meditec, Inc, Dompé US, Inc, Eyevance, Kala Pharmaceuticals, LENSAR, LLC, Lumenis, Omeros Corporation, ScienceBased Health, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and TissueTech, Inc.
Stephen C. Pflugfelder, MD, is a consultant for Allergan, Dompé US, Inc, Kala Pharmaceuticals, KOWA Pharmaceuticals America, Inc, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, and Senju Pharmaceutical Co, Ltd; and is a contracted researcher for Dompé US, Inc, and Novartis Pharmaceuticals Corporation.
Christopher J. Rapuano, MD, is a consultant for Bio-Tissue, Celularity Inc, Dompé US, Inc, Glaukos Corporation, Kala Pharmaceuticals, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and TearLab Corporation; is on the speakers bureau for Bio-Tissue and Dompé US, Inc; and is a contracted researcher for Glaukos Corporation.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Dompé US, Inc.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Dompé US, Inc.
©2021 MedEdicus LLC. 258
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation